In honor of November being Men’s Health Awareness Month, here is a look back at the most impactful developments in the oncology space from 2023.Former ...

Having been a healthier-than-average kid, teen, and young adult, I was poorly prepared to be a good patient as I got older. Not typically running a fever ...

Alex Biese: Hi, my name is Alex Biese. I'm the assistant managing editor of CURE® magazine. In this edition of the Speaking Out® video series, I'm speaking ...

Alex Biese: Hi, my name is Alex Biese. I'm the assistant managing editor of CURE® magazine. In this edition of the Speaking Out® video series, I'm speaking ...

I have recently published my memoir, “Coloring Outside the Lines, Surviving and Thriving with Cancer for 30+ Years.” The first paragraph of the introduction ...

Alex Biese: Hi, my name is Alex Biese. I'm the assistant managing editor of CURE® magazine. In this edition of the Speaking Out® video series, I'm speaking ...

Alex Biese: Hi, my name is Alex Biese, I'm the assistant managing editor of CURE® magazine, and in this edition of the Speaking Out® video series we're ...

Before retiring, I followed the advice to make sure I had a transitional plan of what I was going to do with this new chapter of my life. They say people ...

The Food and Drug Administration (FDA) has been exceptionally busy in November 2023, approving six new treatments in the oncology space — and CURE® covered ...

Velcade (bortezomib), Rituxan (rituximab), cyclophosphamide, doxorubicin hydrochloride, prednisone and cytarabine hydrochloride (VR-CAP) generated improved ...

I am not a nice person. There are some who would even call me a cold hearted b****. A friend once told me he wouldn’t want to meet me in a dark alley and he ...

Datopotamab deruxtecan (Dato-DXd) elicited encouraging responses in patients with heavily pretreated non-small cell lung cancer (NSCLC) harboring actionable ...